Skip to content

Clinical trials

Terminated Leukemia, Myelogenous, Chronic, BCR-ABL Positive trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Leukemia, Myelogenous, Chronic, BCR-ABL Positive Status: Terminated Clear all

140 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20003
200113
20022
20033
20042
20057
20069
200716
20086
20097
20107
20117
20127
20136
201411
20155
20167
20174
20187
20192
20201
20212
20221
20231

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Terminated140

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
M.D. Anderson Cancer Center17
Masonic Cancer Center, University of Minnesota9
Novartis Pharmaceuticals8
National Cancer Institute (NCI)5
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins5
Emory University4
Fred Hutchinson Cancer Center4
Merck Sharp & Dohme LLC4
OHSU Knight Cancer Institute4
Ariad Pharmaceuticals3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Leukemia, Myelogenous, Chronic, BCR-ABL Positive140
Precursor Cell Lymphoblastic Leukemia-Lymphoma61
Leukemia, Myeloid, Acute56
Myelodysplastic Syndromes47
Leukemia46
Leukemia, Lymphocytic, Chronic, B-Cell35
Hodgkin Disease26
Leukemia, Myeloid, Chronic-Phase25
Lymphoma, Non-Hodgkin24
Multiple Myeloma24

Trials

Showing 1 to 25 of 140. Each trial links to its page on Pharma Observatory.

40 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.